Lead-Like | Fragment-Like | Drug-Like | All | Shards | |
---|---|---|---|---|---|
Standard Size Updated | Lead-Like 6,053,287 2014-09-29 | Fragment-Like 847,909 2015-02-04 | Drug-Like 17,900,742 2014-11-24 | All Purchasable 22,724,825 2014-11-28 | Shards 635,159 2014-05-16 |
Clean Size Updated | Clean Leads 4,591,276 2014-09-25 | Clean Fragments 1,611,889 2014-09-24 | Clean Drug-Like 13,195,609 2013-11-05 | All Clean 16,403,865 2013-12-18 | Clean Shards 325,950 2014-11-24 |
In Stock Size Updated | Leads Now 3,687,621 2014-06-25 | Frags Now 704,041 2015-02-04 | Drugs Now 10,639,555 2014-11-24 | All Now 12,782,590 2014-05-01 | Shards Now 424,775 2014-09-24 |
Boutique Size Updated | Boutique Leads 5,114,169 2012-12-24 | Boutique Frags 2,755,555 2013-11-08 | Boutique Drugs 10,292,210 2012-11-27 | All Boutique 12,217,845 2012-11-27 | Boutique Shards 80,698 2013-11-08 |
Comments/Citation |
Teague, Davis, Leeson, Oprea, Angew Chem Int Ed Engl. 1999 Dec 16;38(24):3743-3748.
|
Carr RA, Congreve M, Murray CW, Rees DC, Drug Discov Today. 2005 Jul 15;10(14):987
|
Lipinski, J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):235-49.
|
Purchasable chemical space
|
Type I binding sites
|
Filtering Critieria |
p.mwt <= 350 and p.mwt >= 250 and p.xlogp <= 3.5 and p.rb <= 7
|
p.xlogp <=3.5 and p.mwt <=250 and p.rb <= 5
|
p.mwt <= 500 and p.mwt >= 150 and p.xlogp <= 5 and p.rb <=7 and p.psa < 150 and p.n_h_donors <= 5 and p.n_h_acceptors <= 10
|
|
p.mwt < 190
|